The Future of ADCs Across Gynecologic Cancers

Across gynecologic cancers, the future of antibody drug conjugates appears likely to involve more targets, more refined drug design, and a larger role for rational combinations. The faculty discuss a development landscape shaped by intense clinical trial activity and growing interest in strategies such as dual payloads, dual targets, and combination therapy designed to extend benefit beyond what current agents can achieve alone. At the same time, progress is expected to create new complexity. Once more patients receive these therapies earlier, clinicians will increasingly face questions about resistance, cross resistance, sequencing, and how prior payload exposure influences later treatment choices. The conversation also highlights the importance of linker technology and bystander effect, which may help explain differences in efficacy and toxicity even among agents that seem superficially similar. Rather than focusing on one tumor type, the broader emphasis is on common clinical challenges that cut across endometrial, ovarian, and cervical cancer. Innovation is accelerating, but so is the need for more strategic long term treatment planning.